Do low-molecular-weight heparins improve the survival of cancer patients?

Nature Clinical Practice Oncology

Volumn 2, Issue 12, 2005, Pages 612-613

  Di Nisio, Marcello ^a,c   Buller, Harry R ^b   Porreca, Ettore ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Centro Servizi Biomedici   (Italy)

Author keywords

Low molecular weight heparin; Oral anticoagulants; Survival

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; OUTCOMES RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; STANDARDIZATION; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

EID: 31844437610     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0329     Document Type: Short Survey

References (3)

1. Kakkar AK et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 22: 1944-1948
2. Klerk CP et al. (2005) The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135
3. Altimbas M et al. (2004) A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266-1271